Tissue Plasminogen Activator-Based Thrombolytic Agents

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

Abstract

This chapter focuses on tissue plasminogen activator (tPA)-based product variants approved for general medical use: Alteplase, Reteplase, and Tenecteplase. Fibrinolysis is a proteolytic-mediated process initiated by tPA, which activates the protein plasminogen, thereby forming plasmin. Human tPA was first purified from uterine tissue in 1979, and ensuing immunological studies illustrated that tissue, vascular, and blood-derived plasminogen activators are the same. Alteplase is a first-generation recombinant human tPA approved for general medical use in the United States in 1987. Alteplase is synthesized using the complementary deoxyribonucleic acid for native human tPA derived from a human melanoma cell line. The therapeutic rationale for developing Tenecteplase was the generation of a tPA variant that can be administered intravenously as a rapid single-dose bolus injection. Therapeutic drugs aimed at minimizing the formation and reformation of such thrombi, or accelerating the removal of thrombi once formed, include antiplatelet agents, thrombolytic therapy, and the administration of anticoagulants.

Original languageEnglish
Title of host publicationDirectory of Therapeutic Enzymes
PublisherCRC Press
Pages55-68
Number of pages14
ISBN (Electronic)9781420038378
ISBN (Print)9780849327148
DOIs
Publication statusPublished - 1 Jan 2005

Fingerprint

Dive into the research topics of 'Tissue Plasminogen Activator-Based Thrombolytic Agents'. Together they form a unique fingerprint.

Cite this